Document is current

Article History

Received: 16 February 2023

Accepted: 3 July 2023

First Online: 12 July 2023

Declarations

:

: YT received has received honoraria for lectures from MSD; Ono Pharmaceutical; Nippon Boehringer Ingelheim; Novartis; Takeda; Mitsubishi Tanabe Pharma; Daiichi Sankyo; Sanwa Kagaku Kenkyusho; Kowa Pharmaceutical; Novo Nordisk Pharma; Eli Lilly; Sanofi; Sumitomo Pharma; Bayer, and AstraZeneca, and has obtained research support from MSD; Ono Pharmaceutical; Nippon Boehringer Ingelheim; Novartis; Takeda; Mitsubishi Tanabe Pharma; Daiichi Sankyo; Sanwa Kagaku Kenkyusho; Novo Nordisk Pharma; Eli Lilly; Sanofi; Sumitomo Pharma; Bayer; Astellas; Pfizer; and AstraZeneca. HI received remuneration from Daiichi Sankyo and Nippon Boehringer Ingelheim, and consultancy fees from Daiichi Sankyo. TYamas received research funding from Bristol-Myers Squibb, Bayer, and Daiichi Sankyo, manuscript fees from Daiichi Sankyo, and Bristol-Myers Squibb, and remuneration from Daiichi Sankyo, Bristol-Myers Squibb, Bayer, Ono Pharmaceutical, Novartis, Otsuka Pharmaceutical, and Toa Eiyo. MA received research funding from Bayer and Daiichi Sankyo, and remuneration from Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Bayer, and Daiichi Sankyo. HA received remuneration from Daiichi Sankyo. TI received research funding from Daiichi Sankyo and Bayer, and remuneration from Daiichi Sankyo, Bayer, Nippon Boehringer Ingelheim, and Bristol-Myers Squibb. YK received remuneration from Daiichi Sankyo, Bristol-Myers Squibb, and Nippon Boehringer Ingelheim. KO received remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Medtronic. SS received research funding from Daiichi Sankyo, and remuneration from Bristol-Myers Squibb and Daiichi Sankyo. HT received research funding from Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, IQVIA Services Japan, MEDINET, Medical Innovation Kyushu, Kowa Pharmaceutical, Daiichi Sankyo, Johnson & Johnson, and NEC, consulting fees from Novartis, Ono Pharmaceutical, Bayer, and Nippon Boehringer Ingelheim, remuneration from Kowa Pharmaceutical, Teijin Pharma, Nippon Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Pfizer, Ono Pharmaceutical, Daiichi Sankyo, Novartis, Bayer, Otsuka Pharmaceutical, AstraZeneca, and Nippon Rinsho, and has served in a leadership or fiduciary role in Japanese Heart Failure Society. KT received remuneration from Daiichi Sankyo, Bayer, Bristol-Myers Squibb, Otsuka Pharmaceutical, Novartis, and Abbott Medical. AH participated in a course endowed by Boston Scientific Japan, has received research funding from Daiichi Sankyo and Bayer, and remuneration from Bayer, Daiichi Sankyo, Bristol-Myers Squibb, and Nippon Boehringer Ingelheim. MY received remuneration from Nippon Boehringer Ingelheim and Daiichi Sankyo. TYamag acted as an Advisory Board member of Daiichi Sankyo and received remuneration from Daiichi Sankyo and Bristol-Myers Squibb. ST received research funding from Nippon Boehringer Ingelheim, and remuneration from Daiichi Sankyo, Sanofi, Takeda, Chugai Pharmaceutical, Solasia Pharma, Bayer, Sysmex, Nipro, NapaJen Pharma, Gunze, and Atworking. TK, YM, and AT are employees of Daiichi Sankyo. WS received research funding from Bristol-Myers Squibb, Daiichi Sankyo, and Nippon Boehringer Ingelheim, and remuneration from Daiichi Sankyo, Pfizer, Bristol-Myers Squibb, Bayer, and Nippon Boehringer Ingelheim.

: The ANAFIE Registry was conducted in accordance with the Declaration of Helsinki (registered at UMINCTR: UMIN000024006). The study protocol was approved by the ethics committee at each participating site. The name of the principal ethics committee was The Ethics Committees of The Cardiovascular Institute (Tokyo, Japan) and the number was 299. All participants or their family members/caregivers provided written informed consent to participate.

: Not applicable.